Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Combined Therapy With BRD4 Antagonist and FLT3 Inhibitor Exerts Synergistic Activity Against Cultured and Primary AML Blast Progenitors Expressing FLT-ITD

Melissa Rodriguez, M.D., Ph.D, Warren Fiskus, Ph.D, Sunil Sharma, MD, Jun Qi, PhD, John A Valenta, M.S., Leasha J Schaub, M.S., Bhavin Shah, Santhana Devaraj, Ph.D, Swaminathan Padmanabhan Iyer, MD, James E Bradner, MD, Kapil N. Bhalla, MD

Blood (2013) 122 (21): 3821.

https://doi.org/10.1182/blood.V122.21.3821.3821

Published: 2013

Journal Articles

Combined Therapy With BRD4 Antagonist and JAK Inhibitor Is Synergistically Lethal Against Human Myeloproliferative Neoplasm (MPN) Cells

John A Valenta, M.S., Warren Fiskus, Ph.D, Taghi Manshouri, Ph.D., Sunil Sharma, MD, Jun Qi, PhD, Leasha J Schaub, M.S., Bhavin Shah, Melissa Rodriguez, M.D., Ph.D, Santhana Devaraj, Ph.D, Swaminathan Padmanabhan Iyer, MD, Srdan Verstovsek, MD, PhD, James E Bradner, MD, Kapil N. Bhalla, MD

Blood (2013) 122 (21): 2842.

https://doi.org/10.1182/blood.V122.21.2842.2842

Published: 2013

Journal Articles

BRD4 Antagonist and Histone Deacetylase Inhibitor: A Novel Synergistic Combination Against Human Acute Myeloid Leukemia (AML) Cells

Warren Fiskus, Ph.D, Sunil Sharma, MD, Jun Qi, PhD, John A Valenta, M.S., Leasha J Schaub, M.S., Bhavin Shah, Karissa Peth, Laxmi U.M.R. Jakkula, PhD, Melissa Rodriguez, M.D., Ph.D, Santhana Devaraj, Ph.D, Swaminathan Padmanabhan Iyer, MD, James E Bradner, MD, Kapil N. Bhalla, MD

Blood (2013) 122 (21): 485.

https://doi.org/10.1182/blood.V122.21.485.485

Published: 2013

Journal Articles

Pre-Clinical Efficacy of Combined Therapy with Novel β-Catenin Antagonist BC2059 and Histone Deacetylase Inhibitor Against Cultured and Primary AML Blast Progenitor Cells

Kapil Bhalla, MD, Warren Fiskus, Ph.D., Stephen K. Horrigan, PhD, Sunil Abhyankar, MD, Joseph McGuirk, DO, Sunil Sharma, MD

Blood (2012) 120 (21): 287.

https://doi.org/10.1182/blood.V120.21.287.287

Published: 2012

Journal Articles

Pre-Clinical Efficacy of Combined Therapy with LSD1 Antagonist SP-2509 and Pan-Histone Deacetylase Inhibitor Against AML Blast Progenitor Cells

Warren Fiskus, Ph.D., Sunil Sharma, M.D., Sunil Abhyankar, MD, Joseph McGuirk, DO, David J. Bearss, PhD, Kapil Bhalla, MD

Blood (2012) 120 (21): 868.

https://doi.org/10.1182/blood.V120.21.868.868

Published: 2012

Journal Articles

Targeting Mutant Nucleophosmin (NPM)1: A Promising Approach To Induce Growth Inhibition and Differentiation in Human AML.

Bryan Herger, PhD, Warren Fiskus, Ph.D., Rekha Rao, Ph.D., Kapil Bhalla, M.D.

Blood (2006) 108 (11): 1905.

https://doi.org/10.1182/blood.V108.11.1905.1905

Published: 2006

Journal Articles

Molecular Characterization of Human AML Cells with Resistance to Growth-Inhibitory and Apoptotic Effects of Hydroxamic Acid Analogue Histone Deacetylase Inhibitors.

Fei Guo, Ph.D., Celia Sigua, M.S., Purva Bali, M.S., Warren Fiskus, Ph.D., Gautam Sondarva, Ph.D., Srinivas Annavarapu, M.S., Abdelmoughite Mouttaki, B.S., Peter Atadja, Ph.D., Kapil N. Bhalla, M.D.

Blood (2004) 104 (11): 1171.

https://doi.org/10.1182/blood.V104.11.1171.1171

Published: 2004

Journal Articles

Synergistic Cytotoxic Effects of a Combination of a Novel Tyrosine Kinase Inhibitor AMN107 and Histone Deacetylase Inhibitor LBH589 Against Bcr-Abl Expressing Human Leukemia Cells.

Anna Scuto, Ph.D., Srinivas Annavarapu, M.S., Purva Bali, M.S., Molly McCullers, Warren Fiskus, Ph.D., Abdelmoughite Mouttaki, B.S., Fei Guo, Ph.D., Celia Sigua, M.S., Gautam Sondarva, Ph.D., Peter Atadja, Ph.D., Paul Manley, Ph.D., Kapil N. Bhalla, M.D.

Blood (2004) 104 (11): 1977.

https://doi.org/10.1182/blood.V104.11.1977.1977

Published: 2004

Journal Articles

Molecular Characterization of Human CML Cells with Resistance to the Heat Shock Protein (hsp) 90 Inhibitor 17-Allylamino-Demethoxy Geldanamycin (17-AAG).

Purva Bali, M.S., Warren Fiskus, Ph.D., Fei Guo, Ph.D., Srinivas Annavarapu, M.S., Celia Sigua, M.S., Gautam Sondarva, Ph.D., Abdelmoughite Mouttaki, B.S., Peter Atadja, Ph.D., Paul Manley, Ph.D., Kapil N. Bhalla, M.D.

Blood (2004) 104 (11): 1980.

https://doi.org/10.1182/blood.V104.11.1980.1980

Published: 2004

NARROW

Combined Therapy With BRD4 Antagonist and FLT3 Inhibitor Exerts Synergistic Activity Against Cultured and Primary AML Blast Progenitors Expressing FLT-ITD

Combined Therapy With BRD4 Antagonist and JAK Inhibitor Is Synergistically Lethal Against Human Myeloproliferative Neoplasm (MPN) Cells

BRD4 Antagonist and Histone Deacetylase Inhibitor: A Novel Synergistic Combination Against Human Acute Myeloid Leukemia (AML) Cells

Pre-Clinical Efficacy of Combined Therapy with Novel β-Catenin Antagonist BC2059 and Histone Deacetylase Inhibitor Against Cultured and Primary AML Blast Progenitor Cells

Pre-Clinical Efficacy of Combined Therapy with LSD1 Antagonist SP-2509 and Pan-Histone Deacetylase Inhibitor Against AML Blast Progenitor Cells

Targeting Mutant Nucleophosmin (NPM)1: A Promising Approach To Induce Growth Inhibition and Differentiation in Human AML.

Molecular Characterization of Human AML Cells with Resistance to Growth-Inhibitory and Apoptotic Effects of Hydroxamic Acid Analogue Histone Deacetylase Inhibitors.

Synergistic Cytotoxic Effects of a Combination of a Novel Tyrosine Kinase Inhibitor AMN107 and Histone Deacetylase Inhibitor LBH589 Against Bcr-Abl Expressing Human Leukemia Cells.

Molecular Characterization of Human CML Cells with Resistance to the Heat Shock Protein (hsp) 90 Inhibitor 17-Allylamino-Demethoxy Geldanamycin (17-AAG).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only